Distinguished Healthcare Leaders Placed on Board of Recursion by Occam

In March 2025, Occam Global appointed Namandjé Bumpus, PhD, and Elaine Sun to the Board of Recursion (NASDAQ: RXRX), a leading clinical-stage TechBio company.

Namandjé N. Bumpus served as the FDA’s Principal Deputy Commissioner until the end of 2024, after joining the agency in August 2022 as Chief Scientist. Prior to the FDA, Bumpus was an endowed professor and Chair of the Department of Pharmacology and Molecular Sciences at Johns Hopkins University School of Medicine, where she also served as an Associate Dean. Namandje earned a PhD in Pharmacology from the University of Michigan and completed a postdoctoral fellowship at The Scripps Research Institute.

Elaine Sun is a 30-year life science and financial industry veteran with a proven track record of generating value for both early and late-stage biopharmaceutical companies. She is the current COO and CFO of Mammoth Biosciences, which was co-founded by Nobel laureate and CRISPR pioneer Jennifer Doudna. Previously, she served as SVP and CFO at Halozyme Therapeutics and CFO and Chief Strategy Officer at SutroVax (now Vaxcyte). Elaine began her career in M&A at Evercore Partners and Merrill Lynch. She holds a BA fromWellesley College and an MBA from Harvard Business School.

‍

Read more about Occam's work with Recursion here.

‍

Recent Placements

1. Elaine Sun on the Board of Dynavax
2. Gary Glick as Chairman at CHARM Therapeutics
3. Ellen Lubman as CBO at Werewolf
4. Dawn de los Santos as VP of People at Vestaron
5. Dan Marquess as CSO at Vicinitas Therapeutics
6. Key Financial Executive Placement Expands Global Tech Practice
7. Occam Places Alex Dickinson as Board Member of Gencove